

MEMORANDUM

То:	All Regional Medical Laboratory, Inc. (RML) Clients
From:	Regional Medical Laboratory, Inc. Sonya Bruening, BS, MLT (AMT), Immunology Manager Gerald Miller, PhD, Chief of Immunology
Date:	September 10, 2019

Subject: Measles IgG Update

Increased testing and communication with Public Health, CDC, clinicians and laboratorians has prompted a review of the optimal specificity and sensitivity for measles IgG assays in this new environment of lower vaccination in specific populations and ongoing community exposure. Reexposure to the measles virus induces a strong secondary immune response with a rapid boosting of IgG antibodies which prevents clinical disease. This strong secondary response suggests lower positive IgG responses may provide appropriate protection. Consensus is that an assay for measles IgG should be a sensitive and practicable way to avoid unnecessary vaccination or unnecessary quarantine of exposed individuals. This will reduce the overall economic impact of Measles outbreaks in the community.

Regional Medical Laboratory uses DiaSorin LIAISONXL Measles IgG assay, chemiluminescent immunoassay (CLIA) technology on the LIAISONXL[®] Analyzer. DiaSorin has reassessed the comparator data in light of these new needs and lowered the cut-off and equivocal zone for the assay to increase the agreement for positive results with the comparator assay. Information for the new cut-off has been provided against the current international standard for measles antibody (WHO Third International Standard for Anti-Measles, NIBSC code: 97/648).

Previous cut-off value of Measles IgG 27.5(AU/mL)	New cut-off value of Measles IgG 15(AU/mL)
Previous Neg. concentration of Measles IgG <25(AU/mL)	New Neg. concentration of Measles IgG <13.5(AU/mL)
Previous Positive concentration of Measles $IgG \ge 30(AU/mL)$	New Positive concentration of Measles IgG ≥16.5(AU/mL)
Previous Equivocal concentration of Measles IgG \geq 25 and $<$ 30(AU/mL)	New Equivocal concentration of Measles IgG \geq 13.5 and <16.5(AU/mL)

NEW INTERPRETATION OF RESULTS AS OF 9-6-19

If you have any questions or concerns, contact Dr. Gerald Miller 918-744-2553 or Sonya Bruening 918-744-2500.